The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Projected Increase In Market Value Of The Neuralgia Treatment Market During 2026–2030?
The neuralgia treatment market has demonstrated significant growth in recent years. It is anticipated to increase from $2.43 billion in 2025 to $2.58 billion in 2026, with a compound annual growth rate (CAGR) of 6.1%. Historically, this expansion has been driven by factors such as the rising prevalence of diabetic neuropathy cases, the early adoption of anticonvulsant medications, an increase in opioid-based pain treatments, heightened awareness of neuralgia symptoms, and the expansion of hospital-based pain clinics.
The neuralgia treatment market is anticipated to experience substantial expansion in the coming years, with its size expected to reach $3.38 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This projected increase is driven by several factors, including the rise of minimally invasive surgical solutions for pain, an increasing demand for spinal cord stimulation devices, the growing application of targeted topical therapies, the expansion of telemedicine services for neuralgia care, and advancements in next-generation non-opioid pain medications. Prominent trends observed during this period encompass a greater reliance on drug-based management for neuralgia, increased adoption of nerve block and decompression procedures, a rising preference for topical pain relief treatments, the broader deployment of spinal cord stimulation for chronic neuralgia, and an enhanced focus on early diagnosis and long-term pain management strategies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12921&type=smp
What Key Factors Are Affecting The Neuralgia Treatment Market Demand?
The increasing occurrence of long-term conditions like diabetes is projected to fuel the expansion of the neuralgia treatment market in the future. Chronic illnesses are health issues persisting for at least a year, requiring ongoing medical attention, limiting daily functions, or both. Diabetes is a persistent metabolic disorder marked by elevated blood glucose, also known as blood sugar levels. Treatment for neuralgia is effective against diabetic neuropathy, which refers to nerve damage frequently observed in individuals with diabetes. As an illustration, in March 2024, data from the Office for Health Improvement and Disparities, a UK government body, indicated that from March 2022 to March 2023, the proportion of people with type 1 diabetes undergoing all eight advised care processes grew by 22%, and for those with type 2 diabetes, it saw a 21% rise. Simultaneously, the proportion reaching target HbA1c levels climbed to 37.9%, representing the highest figure ever recorded by the National Diabetes Audit (NDA). Consequently, the escalating incidence of chronic ailments like diabetes is a key factor propelling the expansion of the neuralgia treatment market.
Which Segment Classifications Are Used In The Neuralgia Treatment Market Segment Analysis?
The neuralgia treatment market covered in this report is segmented –
1) By Treatment: Drug-Based, Surgeries
2) By Indication: Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia
3) By Distribution channel: Drug Stores, Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-User: Hospitals And Clinics, Ambulatory Surgery Centers, Other End-Users
Subsegments:
1) By Drug-Based: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2) By Surgeries: Nerve Block Procedures, Decompression Surgery, Neurectomy, Spinal Cord Stimulation
What Trends Are Influencing Changes In The Neuralgia Treatment Market?
Leading companies within the neuralgia treatment market are concentrating on developing advanced solutions, such as peripheral nerve-targeted delivery systems, to improve therapeutic precision, lessen chronic neuropathic pain, and enhance long-term patient outcomes. Peripheral nerve-targeted delivery systems are specialized therapeutic platforms that deliver analgesic or neuromodulatory agents directly to affected nerves, allowing for more precise modulation of pain signals while reducing systemic exposure. For example, in April 2023, in India, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Shingrix, the world’s initial non-live and recombinant subunit vaccine. This vaccine is formulated to prevent shingles and post-herpetic neuralgia in adults aged 50 years and older and is given intramuscularly in two doses. Shingrix combines the antigen glycoprotein E with the adjuvant system AS01B to create a robust and lasting immunological response that helps combat the immune system’s decline with age. Clinical trials have indicated it is 97% effective in preventing shingles in adults. It also effectively guards against post-herpetic neuralgia, a painful complication stemming from shingles.
Which Firms Are Contributing To The Neuralgia Treatment Market Ecosystem?
Major companies operating in the neuralgia treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Purdue Pharma, Dr. Reddy’s Laboratories, Cipla Limited, Hikma Pharmaceuticals plc, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals, Glenmark Pharmaceuticals
Get The Full Neuralgia Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report
Which Region Leads The Neuralgia Treatment Market In Terms Of Market Share?
North America was the largest region in the neuralgia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuralgia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Neuralgia Treatment Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report
Browse Through More Reports Similar to the Global Neuralgia Treatment Market 2026, By The Business Research Company
Artificial Intelligence Ai Software Market Report 2026
Ai Toolkit Market Report
https://www.thebusinessresearchcompany.com/report/ai-toolkit-global-market-report
Generative Ai Software Market Report
https://www.thebusinessresearchcompany.com/report/generative-ai-software-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model